Open AccessSecond-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
Author(s) -
Senthil Rajappa,
KunMing Rau,
Palanki Satya Dattatreya,
Anant Ramaswamy,
Philana Fernandes,
Aarohan Pruthi,
Rebecca Cheng,
Mariusz Lukanowski,
YiHsiang Huang
Publication year - 2022
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v14.i6.1074
Subject(s) - ramucirumab , medicine , cabozantinib , regorafenib , hepatocellular carcinoma , oncology , population , second line treatment , sorafenib , first line treatment , lenvatinib , clinical trial , overall survival , chemotherapy , cancer , colorectal cancer , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom